Medicine and Dentistry
Malignant Neoplasm
97%
Head and Neck Squamous Cell Carcinoma
72%
Breast Cancer
69%
Disease
53%
Neoplasm
46%
Immune Checkpoint Inhibitor
40%
Stomach Cancer
39%
Overall Survival
34%
Metastatic Breast Cancer
32%
Metastatic Carcinoma
27%
Hazard Ratio
26%
Fluorouracil
24%
Cancer Cell
24%
Cisplatin
23%
Chemoradiotherapy
22%
Biological Marker
20%
Hormone Receptor
20%
Palbociclib
20%
Neck
20%
Induction Chemotherapy
20%
Capecitabine
19%
Epidermal Growth Factor Receptor 2
18%
Gamma Urogastrone
18%
Hormone Therapy
17%
Combination Therapy
17%
Ascorbic Acid
16%
Cancer Research
16%
Gefitinib
16%
Stomach Adenocarcinoma
16%
Germinoma
16%
Biliary Tract Cancer
16%
Endodermal Sinus Tumor
16%
Squamous Cell Carcinoma
16%
Breast Carcinoma
16%
Non Small Cell Lung Cancer
16%
Organizing Pneumonia
16%
Premenopause
16%
Spindle Cell Sarcoma
16%
Rheumatoid Arthritis
16%
Lymph Node Metastasis
16%
Supraclavicular Lymph Node
16%
Wernicke's Encephalopathy
16%
Salivary Gland Cancer
16%
Nintedanib
16%
Resuscitation
16%
Etanercept
16%
Retrospective Cohort Study
16%
Hematopoietic Stem Cell Transplantation
16%
Progression Free Survival
16%
Cancer Therapy
14%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Chemotherapy
68%
Head and Neck Squamous Cell Carcinoma
56%
Overall Survival
47%
Breast Cancer
43%
Stomach Cancer
41%
Metastatic Breast Cancer
40%
Disease
38%
Neoplasm
31%
Progression Free Survival
27%
Capecitabine
24%
Tamoxifen
24%
Catenin
24%
Imatinib
24%
Monotherapy
24%
Immune Checkpoint Inhibitor
24%
Ramucirumab
24%
Paclitaxel
24%
Fluorouracil
22%
Biological Marker
20%
Adverse Event
20%
Hormone Receptor
19%
Hepatotoxicity
16%
Cohort Study
16%
Transdermal
16%
Gefitinib
16%
Non Small Cell Lung Cancer
16%
Pancreas Cancer
16%
Duragesic
16%
Chronic Myeloid Leukemia
16%
Biliary Tract Cancer
16%
Tolerability
16%
Erlotinib
16%
Opiate
16%
Wernicke's Encephalopathy
16%
Gemcitabine
16%
Rheumatoid Arthritis
16%
Nintedanib
16%
Salivary Gland Cancer
16%
Etanercept
16%
Survival Rate
13%
Cisplatin
12%
Palbociclib
12%
Neutropenia
11%
Trastuzumab
9%
Primary Tumor
9%
Disease Free Survival
9%
Promyelocytic Leukemia
8%
Eribulin
8%
Biosimilar Agent
8%
Biochemistry, Genetics and Molecular Biology
Circulating Tumor DNA
32%
Cancer Cell
24%
Catenin
24%
Immune Checkpoints
16%
CD44
16%
Gefitinib
16%
Erlotinib
16%
Progression Free Survival
11%
Gene Mutation
10%
Gene Expression
10%
Overall Survival
9%
Epidermal Growth Factor Receptor
8%
Exon
8%
Imatinib
8%
Internet
8%
Genotyping
8%
TSC2
8%
Myeloid
8%
Fluorouracil
8%
MEK Inhibitor
8%
Microarrays
6%
Stem Cell
6%
Gene Frequency
6%
BRCA2
5%
Receptor Tyrosine Kinase Inhibitors
5%
